Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by MrTAteamon Jun 17, 2020 4:50pm
124 Views
Post# 31162091

Questions not answered

Questions not answered
You 03:27 PM 
Dr.Copeland stated that Glenco was established 10 years ago; it is still prerevenue. How did you come up with the valuation?
You 03:32 PM 
Is Sunnybrook working with the protease inhibitors being developed by Amino Therapeutics?
 
You 03:41 PM 
The ELISA test has higher specificity than sensitivity. A screening test should have just the opposite as you would prefer false positives when screening. This ELISA fits more as a confirmatory test,not screening.
 
1. Why did Qsc spend $2 million buying 40% of Amino Therapeutics when they have yet to do any research towards Covid-19( your NR, Due to the recent pandemic Amino has just began the research based on prior published research;No clinical testing has yet been performed related to the potential Treatment) and only $1.5 million to Sunnybrook and Sinai that are actually doing research?
 
2. Any progress at Amino Therapeutics?

You 03:49 PM 
You have the capacity of 4-5 million tests /month. How much more can that be ramped up?
 

<< Previous
Bullboard Posts
Next >>